9月29日，根据港交所最新公告，微医控股有限公司（简称"微医控股"）更新招股书，披露截至2025年6 月30日的最新业绩，继续推进其在联交所的IPO申请进程。 值得一提的是，微医控股曾在2021年4月以及2024年12月先后向港交所提交招股书。此次已是该公司第 三次赴港交所"闯关"。 2010年创立的微医，最初只是一个挂号网站。经过15年发展，它已构建起覆盖在线诊疗、健康管理、医 保控费的完整生态。截至2024年6月，微医连接1.15万家医疗机构、31.8万名医生，服务2.6亿注册用 户，在天津等地打造的"数字健共体"模式，通过AI技术实现医保基金高效利用，糖尿病患者糖化血红蛋 白达标率从17.8%提升至44.2%。 微医控股主要拥有AI医疗服务和线上线下医疗服务两大核心业务。在AI医疗服务领域，以健共体为依 托，采用以签约人员为基础的打包付费模式。公共医疗保险基金设定年度预算，微医与其他健共体参与 者按约定比例分享盈余或分摊亏损。例如在天津，不仅提供健康管理会员服务、云药房服务，还通过增 值服务满足多样化需求。线上线下医疗服务则从免费线上预约系统起步，发展为线上线下融合的诊疗模 式，为个人和企业客户提供全方 ...

Core Insights - The report indicates that China's health technology industry has transitioned from a high-speed development phase to a deep transformation phase, aiming for high-quality evolution [1] - The report focuses on the supply status of the health technology industry in China, analyzing four sub-sectors: nucleic acid drugs, synthetic biology, medical robots, and medical large models [1] - It highlights that China is entering a leading position globally in artificial intelligence drug discovery and development, with domestic companies enhancing their self-research and innovation capabilities [1] - The medical technology market in China is projected to exceed 100 billion in 2024, with steady growth expected despite a slowdown in growth rates from 2025 to 2027 [1] Industry Overview - The report categorizes the health technology industry into upstream (technology-enabled pharmaceuticals, medical devices, and smart hospital R&D), midstream (technology-enabled production and manufacturing), and downstream (technology-enabled service terminals and payment methods) [1] - The report emphasizes the challenges faced by health technology companies in areas such as research innovation, business model transformation, international expansion, and product development [1] Event Highlights - The first Health Technology 50 report was released at a conference in Beijing, where 70 outstanding companies were selected based on field assessments and evaluation models [2] - The event aimed to enhance the visibility and influence of the listed companies within the industry and to create a platform for communication and sharing [2] - Discussions at the event included topics such as artificial intelligence large model technology, digital operation platforms, and digital health ecosystems [2]

Core Insights - The article highlights the significant role of AI in transforming healthcare through the establishment of the Tianjin Digital Health Community, led by Weiyi Holdings, which has become a model for AI healthcare development in China [1][2][5] Group 1: Company Overview - Weiyi Holdings has positioned itself as the largest AI healthcare solution provider in China, with AI medical revenue accounting for 79.21% of total revenue in the first half of 2024, amounting to 1.44 billion yuan [1][6] - The company has seen a consistent increase in revenue from AI medical services, with figures rising from 228 million yuan in 2021 to 1.44 billion yuan in the first half of 2024 [6][7] Group 2: AI Healthcare Model - The Tianjin Digital Health Community, initiated in 2020, has expanded from 266 to 278 medical institutions, including primary, secondary, and tertiary hospitals, showcasing a collaborative approach to healthcare [5][7] - AI has been integrated into various healthcare processes, enhancing the efficiency and accuracy of diagnosis and treatment, with AI doctors achieving a 99.97% compliance rate in reminding doctors about unreasonable prescriptions [5][6] Group 3: Health Outcomes - The implementation of AI in the Tianjin Digital Health Community has led to significant improvements in patient health metrics, such as an increase in the diabetes management success rate from 17.8% to 44.2% [6] - The community has also seen a rise in outpatient visits by 23% to 50%, indicating increased patient engagement and trust in the healthcare services provided [6] Group 4: Future Expansion Plans - Weiyi Holdings plans to replicate the Tianjin model in other cities, having already signed strategic agreements with governments in Guiyang and Yinchuan, with further expansions anticipated in Shanghai and other major cities [7] - The company aims to prioritize partnerships in cities with strong governmental support for healthcare reform, focusing on enhancing healthcare accessibility and quality for patients [7]